OncoMatch/Clinical Trials/NCT07778212
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
Is NCT07778212 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies Orelabrutinib Combined with Pola-R-CHP Regimen for dlbcl - diffuse large b cell lymphoma.
Treatment: Orelabrutinib Combined with Pola-R-CHP Regimen — To evaluate orelabrutinib in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) as first-line treatment for patients with intermediate- to high-risk diffuse large B-cell lymphoma (DLBCL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Neutrophils < 1.5×10⁹/L; Platelets < 75×10⁹/L
Kidney function
Creatinine level higher than 1.5 times the upper limit of normal
Liver function
ALT or AST higher than 2 times the upper limit of normal, AKP and bilirubin higher than 1.5 times the upper limit of normal
Cardiac function
Left ventricular ejection fraction < 50%
Laboratory test values at screening: (unless caused by lymphoma); Neutrophils < 1.5×10⁹/L; Platelets < 75×10⁹/L; ALT or AST higher than 2 times the upper limit of normal, AKP and bilirubin higher than 1.5 times the upper limit of normal; Creatinine level higher than 1.5 times the upper limit of normal; Left ventricular ejection fraction < 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07778212 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify